The appraisal committee considered evidence submitted by Vifor Pharma and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.

WASHINGTON -- Use of the potassium-binding agent patiromer (Veltassa) allowed more heart failure patients at risk for hyperkalemia to remain on optimal therapy with renin-angiotensin-aldosterone ...

WASHINGTON, DC—The oral potassium-binding agent patiromer (Veltassa; Vifor Pharma) may help keep hyperkalemia under control in heart failure with reduced ejection fraction (HFrEF) patients taking ...

Please provide your email address to receive an email when new articles are posted on . “One of the reasons why guideline-directed medical therapy is tough to achieve for renin-angiotensin-aldosterone ...

Several of the core meds for patients with heart failure with reduced ejection fraction (HFrEF) come with a well-known risk of causing hyperkalemia, to which many clinicians respond by pulling back on ...

A newly approved therapy offers the first new option in years to prevent hyperkalemia. The prevalence of diabetes, whether type 1 or type 2, continues to increase at a rapid pace worldwide. According ...

Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin–angiotensin–aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a ...

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent ...

Please provide your email address to receive an email when new articles are posted on . A year-long study of more than 300 patients with hyperkalemia, hypertension, type 2 diabetes, and chronic kidney ...

SAN DIEGO, CA — The investigational oral potassium-binding agent patiromer (Relypsa) was safe and effective in a 1-year, phase 2 study of patients with chronic kidney disease (CKD), type 2 diabetes, ...

New analysis of patients with advanced CKD and resistant hypertension showed that patiromer enables longer use of spironolactone. The following article features coverage from the National Kidney ...

The appraisal committee considered evidence submitted by Vifor Pharma and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.